Arcus Biosciences (RCUS) Operating Leases (2020 - 2022)

Arcus Biosciences' Operating Leases history runs 3 years deep, the most recent figure standing at $119.2 million for Q3 2022.

• In Q3 2022, Operating Leases rose 143.54% year-over-year to $119.2 million; the TTM figure through Sep 2022 stood at $119.2 million (up 143.54% YoY), while the FY2021 annual figure was $116.9 million, up 666.82% from the prior year.
• Operating Leases was $119.2 million for Q3 2022 at Arcus Biosciences, down from $121.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $121.3 million in Q2 2022 to a low of $14.7 million in Q1 2021.
• Historically, Operating Leases has averaged $75.4 million across 3 years, with a median of $83.5 million in 2021.
• Biggest YoY gain for Operating Leases was 680.74% in 2022; the steepest drop was 132.46% in 2022.
• A 3-year view of Operating Leases shows it stood at $15.2 million in 2020, then jumped by 666.82% to $116.9 million in 2021, then increased by 1.97% to $119.2 million in 2022.
• The last three Operating Leases figures came in at $119.2 million (Q3 2022), $121.3 million (Q2 2022), and $114.8 million (Q1 2022), per Business Quant data.